Irish Allergan and Swiss Novartis have agreed to start a proof-of-concept study of a combination of their NASH candidates cenicriviroc (Allergan) and FXR agonist LJN452 (Novartis).
sphingotec GmbH and bestbion dx GmbH have signed an agreement to market sphingotec’s innovative sepsis and congestive heart failure test (sphingotest bio-ADM) and acute kidney function monitoring assay (sphingotest penKid) in Germany and Austria.
Following its CHF1.901bn IPO at SIX Swiss Exchange on 7 April, Galenica Santé has announced full excercise of the over-allotment option worth CHF248m.
Spanish Economy Minister Luis de Guindos and EMBL Director-General Iain Mattaj have inked an agreement to host a world-class tissue imaging facility in Barcelona. The EMBL’s 6th site in Europe will start work in September.
After having received market authorisation in Europe and the US for alectinib as second-line treatment for ALK-positive NSCLC, Roche presents data that qualifies the oral drug as first-line therapy.
French cancer specialist Nanobiotix has closed a €25.1m placement of shares being issued to qualified and institutional investors in the US and Europe. The company will use to funds go push commercialisation of its lead candidate NBTXR3.
As cancer immune therapy specialist Adaptimmune’s R&D pipeline has expanded from 9 to 11 candidates and R&D cost rose from US$40.5m to US$63.8m, the company needed more funds.
Menarini-Silicon Biosystems Inc., a wholly owned subsidiary of Bologna-based Menarini Group, has completed the take-over of the Cellsearch Circulating Tumour Cell System from Janssen Diagnostics.
Japanese pharma major Astellas has announced it will take over private Belgian drug developer Ogeda S.A. for €800m.
Genmab A/S has announced that its CD38-targeting Phase II candidate daratumab did not reach the expected ORR in non-Hodgkin’s lymphoma patients. Co-developer Janssen has decided to terminate development in three NHL subtypes.